ZhuZhou QianJin PharmaceuticalLtd Management
Management criteria checks 3/4
ZhuZhou QianJin PharmaceuticalLtd's CEO is Zhiyong Chen, appointed in Jun 2023, has a tenure of 1.58 years. directly owns 0.018% of the company’s shares, worth CN¥806.68K. The average tenure of the management team and the board of directors is 4.5 years and 2.8 years respectively.
Key information
Zhiyong Chen
Chief executive officer
CN¥915.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.5yrs |
| Board average tenure | 2.8yrs |
Recent management updates
CEO
Zhiyong Chen (47 yo)
1.6yrs
Tenure
CN¥915,200
Compensation
Mr. Zhiyong Chen is General Manager of ZhuZhou QianJin Pharmaceutical Co.,Ltd from June 20, 2023. He was Deputy General Manager of ZhuZhou QianJin Pharmaceutical Co.,Ltd from November 28, 2014 to December...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| General Manager | 1.6yrs | CN¥915.20k | 0.018% CN¥ 806.7k | |
| Deputy GM | 20.5yrs | CN¥848.30k | 0.028% CN¥ 1.2m | |
| Deputy General Manager | no data | CN¥325.80k | 0.011% CN¥ 496.3k | |
| Deputy General Manager | no data | CN¥336.00k | 0.011% CN¥ 496.3k | |
| Financial Controller and Deputy General Manager | no data | CN¥325.00k | 0.011% CN¥ 496.3k | |
| Board secretary | 4.5yrs | CN¥612.50k | 0.028% CN¥ 1.2m |
4.5yrs
Average Tenure
47yo
Average Age
Experienced Management: 600479's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy GM | 9.7yrs | CN¥848.30k | 0.028% CN¥ 1.2m | |
| Chairman | 8.7yrs | CN¥1.17m | no data | |
| Director | 2.8yrs | no data | no data | |
| Director | 2.3yrs | no data | no data | |
| Director | less than a year | no data | no data |
2.8yrs
Average Tenure
53yo
Average Age
Experienced Board: 600479's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 11:39 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ZhuZhou QianJin Pharmaceutical Co.,Ltd is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhengwu Wu | AJ Securities Co., Ltd |
| Changming He | BOCI Research Ltd. |
| Pei Hui Tang | Chasing Securities |